Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

[1] Buse DC(2013)Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study Headache 53 1278-1299

[2] Loder EW(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349

[3] Gorman JA(2001)Epidemiology and economic impact of migraine Curr Med Res Opin 17 s4-s12

[4] Stewart WF(2018)Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19 17-1169

[5] Reed ML(2010)Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan Cephalalgia 30 1159-234

[6] Fanning KM(2017)Lasmiditan for the treatment of migraine Expert Opin Investig Drugs 26 227-54

[7] Lipton RB(2015)The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine Ther Adv Neurol Disord 8 46-97

[8] Bigal ME(2018)Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186 88-e2232

[9] Diamond M(2018)Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study Neurology 91 e2222-1904

[10] Freitag F(2019)Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine Brain 142 1894-966

[1] Buse DC(2013)Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study Headache 53 1278-1299

[2] Loder EW(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349

[3] Gorman JA(2001)Epidemiology and economic impact of migraine Curr Med Res Opin 17 s4-s12

[4] Stewart WF(2018)Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19 17-1169

[5] Reed ML(2010)Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan Cephalalgia 30 1159-234

[6] Fanning KM(2017)Lasmiditan for the treatment of migraine Expert Opin Investig Drugs 26 227-54

[7] Lipton RB(2015)The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine Ther Adv Neurol Disord 8 46-97

[8] Bigal ME(2018)Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186 88-e2232

[9] Diamond M(2018)Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study Neurology 91 e2222-1904

[10] Freitag F(2019)Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine Brain 142 1894-966